Medical disclaimer: Peptide Clinic Finder is an informational directory and does not diagnose, prescribe, or recommend treatments. Always consult a qualified clinician for medical decisions.

CJC-1295 vs Sermorelin

Both are growth hormone-releasing peptides used in hormone optimisation and longevity clinic contexts. Compare clinic profiles by protocol transparency and clinician oversight.

CJC-1295 and sermorelin are commonly referenced in hormone optimisation and longevity clinics. Providers vary in dosing rationale and monitoring standards. Use this comparison to assess clinical governance.

CJC-1295

A growth hormone secretagogue referenced in longevity and hormone optimisation listings.

Potential benefits

  • Often part of GH secretagogue protocols.
  • Common in performance and longevity clinics.

Considerations

  • Evidence base varies by clinic.
  • Monitoring standards differ.
Best for: Comparing hormone optimisation clinics and their oversight.

Sermorelin

A growth hormone–releasing hormone analogue listed in longevity protocols.

Potential benefits

  • Referenced in hormone optimisation pathways.
  • Often grouped with other secretagogues.

Considerations

  • Clinical context varies widely.
  • Requires structured assessment.
Best for: Evaluating clinics that list GH secretagogues.
CategoryCJC-1295Sermorelin
Directory contextRecovery / performance-focused listing context.Weight / metabolic or longevity listing context.
Common goalsRecovery support, injury pathways, performance.Weight management, metabolic health, longevity programs.
Guidance noteInformational listing only; suitability requires clinician review.Informational listing only; suitability requires clinician review.

Related clinics

Conclusion

Both appear in similar clinic contexts; choose based on provider quality and monitoring standards rather than the peptide name alone.

Related peptide pages